Key result
Spironolactone significantly increased ejection fraction from 25.7% to 33.3% (P=0.002) over six months in CAPD patients with heart failure, with one exclusion for hyperkalemia.
Why the study?
Does spironolactone improve ejection fraction and maintain safe potassium levels in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis?
RCT (n=18)
Double-blind
randomly assigned
No
Does spironolactone improve ejection fraction and maintain safe potassium levels in patients with advanced congestive heart failure on continuous ambulatory peritoneal dialysis?
Absolute Event Rate: 33.3% vs 34.2%
p-value: p=0.002
Spironolactone 25 mg every other day significantly improved ejection fraction in CAPD patients with advanced heart failure, though careful potassium monitoring is required.
No takes yet. Share an insight, caveat, or question.
Supports spironolactone for EF gains in CAPD HF with potassium monitoring; extends MRA RCT evidence to peritoneal dialysis.
Taheri et al. (2012) conducted an RCT in Congestive heart failure in patients on continuous ambulatory peritoneal dialysis (n=18). spironolactone vs. placebo was evaluated on ejection fraction (EF) (p=0.002). Spironolactone significantly increased ejection fraction from 25.7% to 33.3% (P=0.002) over six months in CAPD patients with heart failure, with one exclusion for hyperkalemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: